Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2825 vs Immunotherapy in Relapsed/Refractory Follicular Lymphoma
NCT07187960Phase 3Not yet recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tqb2825 in follicular lymphoma (FL), sponsored by Chia Tai Tianqing. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tqb2825
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07187960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187960.